Liver Cancer
Conditions
Keywords
childhood hepatocellular carcinoma, childhood liver cancer, adult primary liver cancer, adult primary hepatocellular carcinoma
Brief summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in stored tumor samples from younger patients with liver cancer.
Detailed description
OBJECTIVES: * To characterize, at a molecular level, archived samples of tissue from young patients with fibrolamellar carcinoma and hepatocellular carcinoma in non-cirrhotic livers matched for age and sex. * To perform genomic analysis on these tissue samples using array comparative genomic hybridization. * To perform targeted gene mutation analysis on these samples by PCR. * To perform proteomic profiling on fixed tissues in these samples by various proteomic methods, including IHC and mass spectrometry. * To look for association between molecular aberrations and clinicopathologic features in these samples. OUTLINE: Archived tissue samples are collected from the pathology department at Vanderbilt University Medical Center and from the Mayo Clinic in Rochester, Minnesota. Tissue samples are analyzed by genomic analysis using array comparative genomic hybridization, target gene mutation analysis by PCR, and proteomic profiling on fixed tissues using various proteomic methods, including IHC and mass spectrometry. Samples are also examined for association between molecular aberrations and clinicopathologic features found in each disease. Clinical patient data (i.e., age, sex, race, date of diagnosis, risk factors, histology, surgical staging, follow-ups, date of death, and adjuvant therapy) are also collected.
Interventions
GENETICcomparative genomic hybridization
GENETICmolecular genetic technique
GENETICmutation analysis
GENETICpolymerase chain reaction
Not noted
GENETICproteomic profiling
OTHERimmunohistochemistry staining method
not noted
OTHERlaboratory biomarker analysis
not noted
OTHERmass spectrometry
not noted
OTHERmedical chart review
not noted
Sponsors
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Diagnosis of fibrolamellar carcinoma or hepatocellular carcinoma in a non-cirrhotic liver * Archived tumor specimens available for analysis from Vanderbilt University or Mayo Clinic
Exclusion criteria
* Not specified PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification of proteomic profiles and molecular pathways involved in tumor progression | After collection of tissue samples | Genomic analysis, targeted gene mutation analysis, immunohistochemistry, and mass spectrometry will be employed to identify proteomic profiles and specific molecular pathways involved in tumor progression of fibrolamellar carcinoma and hepatocellular carcinoma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Association between fibrolamellar carcinoma and hepatocellular carcinoma in terms of molecular aberrations and clinicopathologic features | After molecular analysis of tissue and after collection of clinicopathologic data | Compare and contrast fibrolamellar carcinoma with hepatocellular carcinoma in terms of the molecular differences, tissue pathologies, and medical histories. |
Outcome results
None listed